KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EPS (Basic) (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EPS (Basic) for 9 consecutive years, with $1.17 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 1000.0% year-over-year to $1.17, compared with a TTM value of $1.26 through Dec 2025, up 393.02%, and an annual FY2025 reading of $1.26, up 393.02% over the prior year.
  • EPS (Basic) was $1.17 for Q4 2025 at Biocryst Pharmaceuticals, up from $0.07 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.17 in Q4 2025 and bottomed at -$0.84 in Q4 2023.
  • Average EPS (Basic) over 3 years is -$0.0, with a median of -$0.06 recorded in 2024.
  • The sharpest move saw EPS (Basic) surged 84.52% in 2024, then surged 1000.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.84 in 2023, then soared by 84.52% to -$0.13 in 2024, then surged by 1000.0% to $1.17 in 2025.
  • Business Quant data shows EPS (Basic) for BCRX at $1.17 in Q4 2025, $0.07 in Q3 2025, and $0.02 in Q2 2025.